Skip to main content
Log in

Fatigue – Tumorerschöpfung

Ein unabwendbares Schicksal?

Fatigue – cancer-related exhaustion

An unavoidable destiny?

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Hintergrund

Obwohl die subjektive Todesbedrohung von Betroffenen und Nichtbetroffenen kaum abgenommen hat, überleben heute mehr als die Hälfte aller Tumorpatienten ihre Erkrankung. Auch wenn die Anstrengungen zur Verbesserung der Therapieergebnisse nicht nachlassen dürfen, rücken nun vermehrt Fragen zur Qualität des Überlebens, Quality of Survivorship, in den Fokus der Behandler. Dabei spielt die Tumorerschöpfung als schwerwiegende Nebenwirkung, die mit einer Krebserkrankung einhergeht, eine zentrale Rolle.

Ziel

Darstellung der aktuellen Ansichten der Ursachen, Symptomatik und Behandlung der Fatigue.

Material und Methoden

Die Übersicht basiert auf Literaturrecherchen und Erfahrungen und Erkenntnissen der Deutschen Fatigue Gesellschaft.

Ergebnisse

Nahezu bei allen Patienten unter Therapie und bei bis zu 40 % der Patienten, je nach Entität, auch Jahre nach erfolgreicher Therapie tritt eine Erschöpfung auf, die eine erhebliche Auswirkung auf die Lebensqualität hat und wahrscheinlich auch den Therapieverlauf beeinflusst. Wesentlich ist die möglichst exakte Diagnose und klare Abgrenzung zur Depression oder des chronischen Fatigue-Syndroms (CFS) nach Ausschluss somatischer Ursachen. Erfreulicherweise gelingt es mittels der zur Verfügung stehenden Fragebogeninstrumente zuverlässig und reproduzierbar das Vorliegen und den Verlauf einer tumorbedingten Fatigue zu erfassen.

Schlussfolgerungen

Die Behandlung des Syndroms umfasst neben der Korrektur zugrunde liegender Stoffwechselstörungen v. a. körperliches Training und psychoonkologische Maßnahmen zur Verbesserung der Krankheitsbewältigung. Die medikamentösen Behandlungsansätze sind in den letzten Jahren fundierter geworden. Allerdings besteht noch kein Konsens über ein klar definiertes Therapieregime.

Abstract

Background

More than a half of all cancer patients survive their malignant disease, but the fear of pending death for a patient and their relatives has changed little. Maintaining the efforts to improve treatment results, issues on quality of survivorship should be increasingly addressed by those providing treatment. The cancer-related exhaustion, as a severe side effect, plays a central role.

Objective

Description of current views of causes, symptoms and treatment of fatigue.

Materials and methods

The review is based on a literature search and on the expertise and knowledge of the German Fatigue Society.

Results

Almost all tumor patients undergoing treatment and even years after successful treatment approximately 40 % of tumor patients, depending on entity, report fatigue as having a significant impact on quality of life and perhaps also on prognosis. A precise diagnosis, exclusion of somatic causes and differentiation between the tumor-associated fatigue, depression or chronic fatigue syndrome are essential for further treatment. Fortunately, available questionnaires allow an evaluation of manifestation and course of the tumor-related fatigue.

Conclusion

The treatment of this syndrome comprises, after adjusting metabolic disorders, physical exercise and psycho-oncological care for improvement of disease coping. During recent years, pharmacological treatment approaches have become more evidence based. However, general agreement on a treatment strategy is still not available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365

    Article  PubMed  CAS  Google Scholar 

  2. Bloom JR, Fobair P, Gritz E et al (1993) Psychosocial outcomes of cancer: a comparative analysis of Hodgkin’s disease and testicular cancer. J Clin Oncol 11:979

    PubMed  CAS  Google Scholar 

  3. Burks TF (2001) New agents for the treatment of cancer-related fatigue. Cancer 92(6 Suppl):1714

    Article  PubMed  CAS  Google Scholar 

  4. Cella D (1997) The functional assessment of cancer therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34(3 Suppl 2):13

    PubMed  CAS  Google Scholar 

  5. Cella D, Davis K, Breitbart W, Curt G (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19:3385

    PubMed  CAS  Google Scholar 

  6. Cella D, Lai JS, Chang CH (2002) Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94:528

    Article  PubMed  Google Scholar 

  7. Curt GA (2000) The impact of fatigue on patients with cancer: overview of fatigue 1 and 2. Oncologist 5:9

    Article  Google Scholar 

  8. Dimeo FC (2001) Effects of exercise on cancer-related fatigue. Cancer 92(6 Suppl):1689

    Article  PubMed  CAS  Google Scholar 

  9. Fobair P, Hoppe RT, Bloom J et al (1986) Psychosocial problems among survivors of Hodgkin’s disease. J Clin Oncol 4:805

    PubMed  CAS  Google Scholar 

  10. Glaus A (1998) Fatigue in patients with cancer. Analysis and assessment. Recent Results Cancer Res 145:172

    Google Scholar 

  11. Hann DM, Jacobsen PB, Azzarello LM et al (1998) Measurement of fatigue in cancer patients: development and validation of the fatigue symptom inventory. Qual Life Res 7:301

    Article  PubMed  CAS  Google Scholar 

  12. Heim ME, Krauss O, Schwarz R (2001) Effect of cancer in rehabilitation on fatigue and quality of life parameters. Psycho-Oncology 10:26

    Google Scholar 

  13. Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 18:893

    PubMed  CAS  Google Scholar 

  14. Joly F, Henry-Amar M, Arveux P et al (1996) Late psychosocial sequelae in Hodgkin’s disease survivors: a French population-based case-control study. J Clin Oncol 14:2444

    PubMed  CAS  Google Scholar 

  15. Knobel H, Havard-Loge J, Brit-Lund M et al (2001) Late medical complications and fatigue in Hodgkin’s disease survivors. J Clin Oncol 19:3226

    PubMed  CAS  Google Scholar 

  16. Kornblith AB, Anderson J, Cella DF et al (1990) Quality of life assessment of Hodgkin’s disease survivors: a model for cooperative clinical trials. Oncology 4:93

    PubMed  CAS  Google Scholar 

  17. Kurzrock R (2001) The role of cytokines in cancer-related fatigue. Cancer 92(6 Suppl):1684

    Article  PubMed  CAS  Google Scholar 

  18. Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S (1999) Hodgkin’s disease survivors more fatigued than the general population. J Clin Oncol 17:253

    PubMed  CAS  Google Scholar 

  19. McNeil C (2001) Cancer fatigue: one drug fails but more are in the pipeline. J Natl Cancer Inst 93:892

    Article  PubMed  CAS  Google Scholar 

  20. Mendoza TR, Wang XS, Cleeland CS et al (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85:1186

    Article  PubMed  CAS  Google Scholar 

  21. Okuyama T, Akechi T, Kugaya A et al (2000) Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manage 19:5

    Article  PubMed  CAS  Google Scholar 

  22. Piper B, Lindsey A, Dodd M et al (1989) The development of an instrument to measure the subjective dimension of fatigue. In: Funk S, Tornquist E, Champagne M et al (Hrsg) Key aspects of comfort: management of pain, Fatigue And Nausea. Springer, New York

  23. Rüffer JU, Flechtner H, Josting A et al (in press) Fatigue in patients with Hodgkin’s disease: a report from the German Hodgkin Lymphoma Study Group (GHSG)

  24. Schwartz AL (1998) The Schwartz cancer fatigue scale: testing reliability and validity. Oncol Nurs Forum 25:711

    PubMed  CAS  Google Scholar 

  25. Servaes P, Werf S van der, Prius J et al (2001) Fatigue in disease-free cancer patients compared with fatigue in patients with chronic fatigue syndrome. Support Care Cancer 9:11

    Article  PubMed  CAS  Google Scholar 

  26. Smets EM, Garssen B, Bonke B, De-Haes JC (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39:315

    Article  PubMed  CAS  Google Scholar 

  27. Visser MR, Smets EM (1998) Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer 6:101

    Article  PubMed  CAS  Google Scholar 

  28. Ware J Jr, Sherbourne C (1992) The MOS 36-item short-form health survey (SF-36): I. conceptual framework and item selection. Med Care 30:473

    Article  PubMed  Google Scholar 

  29. Weis J 2011 Cancer-related fatigue: prevalence, assessment and treatment strategies. Expert Rev Pharmacoecon Outcomes Res 11:441–446

    Google Scholar 

  30. Weis J, Arraras JI, Conroy T et al (2012) Development of an EORTC quality of life phase III module measuring cancer-related fatigue (EORTC QLQ-FA13). Psychooncology. doi:10.1002/pon.3092 (Epub ahead of print)

  31. (o A) (2011) Deutsche Krebsgesellschaft: Richtlinien für die Anwendung von Sport und körperlicher Aktivität in der Prävention, supportiver Therapie und Rehabilitation neoplastischer Erkrankungen Teil II. Forum 5:9–12

    Google Scholar 

  32. McNeely ML, Courneya KS (2010) Exercise programs for cancer-related fatigue: evidence and clinical guidelines. J Natl Compr Canc Netw 8:945–953

    PubMed  Google Scholar 

  33. Horneber M, Fischer I, Dimeo F et al (2012) Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. Dtsch Arztebl Int 109(9):161–171 (quiz 172). doi:10.3238/arztebl.2012.0161 (Epub 2012 Mar 2)

    PubMed  Google Scholar 

  34. Bennett B, Goldstein D, Friedlander M et al (2007) The experience of cancer-related fatigue and chronic fatigue syndrome: a qualitative and comparative study. J Pain Symptom Manage 34(2):126–135

    Article  PubMed  Google Scholar 

  35. Fluge Ø, Bruland O, Risa K et al (2011) Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One 6(10):e26358. doi:10.1371/journal.pone.0026358 (Epub 2011 Oct 19)

    Article  PubMed  CAS  Google Scholar 

  36. Rüffer JU, Flechtner H (2006) Deutsche Fatigue Gesellschaft. Fatigue – Diagnostik, klinische Implika tionenund Thera pie. Onkologe 12:36–40

    Article  Google Scholar 

  37. Bruera E (2010) Cancer-related fatigue: a multidimensional syndrome. J Support Oncol 8:175–176

    PubMed  Google Scholar 

  38. Barsevick A, Frost M, Zwinderman A et al (2010) I’m so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res 19:1419–1427

    Article  PubMed  Google Scholar 

  39. Radbruch L, Strasser F, Elsner F et al (2008) Fatigue in palliative care patients – an EAPC approach. Palliat Med 22:13–32

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seinen Koautor an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J.U. Rüffer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rüffer, J., Adamietz, I. Fatigue – Tumorerschöpfung. Onkologe 19, 279–289 (2013). https://doi.org/10.1007/s00761-012-2408-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-012-2408-6

Schlüsselwörter

Keywords

Navigation